Remestemcel
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Remestemcel, sold under the brand name Ryoncil, is an allogeneic bone marrow-derived mesenchymal stromal cell therapy used for the treatment of graft-versus-host disease. Remestemcel contains mesenchymal stromal cells, which are a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. These mesenchymal stromal cell are isolated from the bone marrow of healthy adult human donors. The most common adverse reactions include viral infectious disorders, bacterial infectious disorders, infection – pathogen unspecified, pyrexia, hemorrhage, edema, abdominal pain, and hypertension. Remestemcel was approved for medical use in the United States in December 2024. Remestemcel is the first mesenchymal stromal cell therapy approved by the US Food and Drug Administration.
Remestemcel, sold under the brand name Ryoncil, is an allogeneic bone marrow-derived mesenchymal stromal cell therapy used for the treatment of graft-versus-host disease. Remestemcel contains mesenchymal stromal cells, which are a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. These mesenchymal stromal cell are isolated from the bone marrow of healthy adult human donors. The most common adverse reactions include viral infectious disorders, bacterial infectious disorders, infection – pathogen unspecified, pyrexia, hemorrhage, edema, abdominal pain, and hypertension. Remestemcel was approved for medical use in the United States in December 2024. Remestemcel is the first mesenchymal stromal cell therapy approved by the US Food and Drug Administration.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338512412 under CC BY-SA 4.0; modifications have been made.